

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspio.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. | |
|--|-----------------|----------------------|------------------------|-----------------------|--|
| 10/826,130 | 04/16/2004 | Ajamete Kaykas | UWOTL122738 | 8693 | |
| 26389 | 7590 06/28/2005 | | EXAMINER | | |
| CHRISTENSEN, O'CONNOR, JOHNSON, KINDNESS, PLLC | | | WOLLENBERG | WOLLENBERGER, LOUIS V | |
| 1420 FIFTH A | VENUE | | | | |
| SUITE 2800 SEATTLE, WA 98101-2347 | | | ART UNIT | PAPER NUMBER | |
| | | | 1635 | | |
| | | | DATE MAILED: 06/28/200 | 5 | |

Please find below and/or attached an Office communication concerning this application or proceeding.

| | Application No. | Applicant(s) | | | |
|--|---|--|--|--|--|
| | 10/826,130 | KAYKAS ET AL. | | | |
| Office Action Summary | Examiner | Art Unit | | | |
| | Louis V. Wollenberger | 1635 | | | |
| The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply | | | | | |
| A SHORTENED STATUTORY PERIOD FOR REP THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a re - If NO period for reply is specified above, the maximum statutory perior - Failure to reply within the set or extended period for reply will, by statu Any reply received by the Office later than three months after the maili- earned patent term adjustment. See 37 CFR 1.704(b). | | nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133). | | | |
| Status | | | | | |
| 1) Responsive to communication(s) filed on 16 | April 2004. | | | | |
| 2a) This action is FINAL . 2b) ⊠ Th | This action is FINAL . 2b)⊠ This action is non-final. | | | | |
| • | Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. | | | | |
| Disposition of Claims | | | | | |
| 4) ⊠ Claim(s) <u>1-34</u> is/are pending in the application 4a) Of the above claim(s) is/are withdrest 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) <u>1-34</u> are subject to restriction and/or | awn from consideration. | | | | |
| Application Papers | | | | | |
| 9) The specification is objected to by the Examiner. | | | | | |
| 10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner. | | | | | |
| Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). | | | | | |
| Replacement drawing sheet(s) including the corre | • | | | | |
| Priority under 35 U.S.C. § 119 | | | | | |
| 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bure * See the attached detailed Office action for a list | nts have been received. nts have been received in Applicat fority documents have been receive au (PCT Rule 17.2(a)). | ion No ed in this National Stage | | | |
| Attachment(s) 1) Notice of References Cited (PTO-892) | 4) ☐ Interview Summary Paper No(s)/Mail D | | | | |
| 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0 Paper No(s)/Mail Date | | Patent Application (PTO-152) | | | |

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1–16, and 33, drawn to an expression vector, comprising first and second RNA polymerase III promoters and first and second RNA polymerase III termination signals, classified in class 536, subclass 23.1, for example.
- II. Claims 17–19, drawn to a method for inhibiting expression of a target gene, classified in class 514, subclass 44.
- III. Claims 20–32, drawn to methods for determining the effect of an siRNA on a biological process, and to methods for identifying an siRNA that affects a biological process, classified in class 435, subclass 6.
- IV. Claim 34, drawn to a kit comprising first and second primers and a doublestranded nucleic acid template, classified in class 536, subclass 23.1, for example.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of

using that product (MPEP § 806.05(h)). In the instant case, the expression vector of Group I can be used as a molecular weight marker in Southern gels, which does not require introducing the vector into cells to inhibit gene expression, as in Group II.

Page 3

Inventions I and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the expression vector of Group I can be used as a molecular weight marker in Southern gels, which does not require introducing the vector into cells, as in Group III.

Inventions I and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the inventions are drawn to physically and functionally distinct products that are not disclosed as useful together and that have different functions and effects. For example, Group I is drawn to a complete expression vector comprising RNA polymerase promoters and termination signals, whereas Group II is drawn to a kit for creating expression vectors. The kit comprises two PCR primers and a nucleic acid template, which are physically and functionally distinct from the expression vector of Invention I and are not disclosed as being capable of use together with the expression vector of Invention I.

Art Unit: 1635

Inventions II and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are unrelated because the inventions are not disclosed as useful together, and because they have different modes of operation and function. For example, the method of inhibiting the expression of a target gene, according to Invention II, requires the use of defined siRNAs having known inhibitory profiles, whereas the methods of determining or identifying the biological activity of an siRNA, as in Invention III, requires testing a large number of undefined (i.e., uncharacterized) siRNAs having unknown inhibitory profiles.

Inventions II and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are unrelated because they are not disclosed as useful together and because they have different modes of operation and effect. For example, Invention II is drawn to a method of inhibiting the expression of a target gene, comprising the use of an expression vector containing a gene-specific insert, whereas Invention IV is drawn to a kit for creating an siRNA expression vector. The kit comprises two PCR primers and a nucleic acid template, which are not disclosed as being capable of direct use in the method of Invention II.

Inventions III and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of

٠

operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are unrelated because they are not disclosed as useful together and because they have different modes of operation and effect. For example, Invention III is drawn to methods of determining the biological activity of an siRNA, and to methods of identifying siRNAs that have a biological effect, whereas Invention IV is drawn to a kit for creating an siRNA expression vector. The kit comprises two PCR primers and a nucleic acid template, which are not disclosed as being capable of direct use in the method of Invention III.

Furthermore, searching each of these inventions together in a single application imposes a serious burden on the examiner because the searches required are divergent and not coextensive. Thus, because these inventions are distinct for the reasons given above and because the searches are divergent and not coextensive, restriction for examination purposes as indicated is proper.

Rejoinder

The examiner has required restriction between product and process claims.

Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance,

Art Unit: 1635

whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Conclusion

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Louis V. Wollenberger whose telephone number is 571-272-8144. The examiner can normally be reached on Mon-Fri, 8:00 am-4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's acting supervisor, Andrew Wang can be reached on 571-272-0811. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval system (PAIR). Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you

Application/Control Number: 10/826,130 Page 8

Art Unit: 1635

have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. For more information about the PAIR system, see http://pair-direct.uspto.gov.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

LVW June 22, 2005

Louis V. Wollenberger, Ph.D.

Examiner

Art Unit 1635

TECHNOLOGY CENTER 1600